FDA Releases Online Course on Biosimilars
The course, intended for healthcare professionals, provides an overview of biosimilar products and FDA’s biosimilar product development programs.
On Feb. 18, 2016, FDA released an online resource for health care professionals on biosimilars. The CDERLearn continuing education (CE) credit course for health care professionals on biosimilars is titled FDA Overview of Biosimilar Products.
The 90-minute course is intended to help health care professionals make informed decisions when considering, prescribing, or dispensing biosimilar products. The course also provides a general review of FDA’s process for biosimilar product development programs.
The course will give a basic overview of the regulations granting FDA authority to review and approve biosimilar products, and information about the science-based approach the FDA has taken to support biosimilar development. FDA stated that the target audience for the course is healthcare professionals, including physicians, physician assistants, nurses, nurse practitioners, and pharmacists.
In a press announcement from the agency, FDA said that its “high standard for approval of biosimilar products means that patients and healthcare professionals can rely upon the safety and effectiveness of a biosimilar product, just as they would the reference product.” The course is available for free on FDA’s website.
Source: FDA
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.
